Posted by Michael Wonder on 31 May 2021
BrainSee novel software is breakthrough for non-invasive detection and monitoring of Alzheimer’s disease at the early stage of mild cognitive impairment
28 May 2021 - Darmiyan’s AI solution reliably guides physicians on prognosis and clinical management of mild cognitive impairment patients.
The FDA has granted breakthrough status to BrainSee, a new AI powered product by Darmiyan. Using standard, non-invasive clinical brain MRI (no injection and no radiation), BrainSee detects Alzheimer’s disease at the early prodromal stage, enabling timely medical interventions and care planning.
Such early detection or rule-out of Alzheimer’s disease non-invasively and affordably is nonexistent in the clinical market today.
